Pembrolizumab Shows Survival Benefit for Patients With Renal Cancer

WEDNESDAY, Jan. 31, 2024 -- For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news